PDF herunterladen
CC BY-NC-ND 4.0 · Int Arch Otorhinolaryngol 2021; 25(01): e108-e114
DOI: 10.1055/s-0040-1708898
Original Research

Time between Diagnosis and Treatment of Hypopharynx and Larynx Cancer: Are Longer Delays Associated with Higher Discrepancy between Clinical and Pathological Staging?

Mariline Santos 
1   Department of Otolaryngology, Head and Neck Surgery, Centro Hospitalar e Universitário do Porto, Porto, Portugal
,
Eurico Monteiro 
2   Department of Otolaryngology, Head and Neck Surgery, Portuguese Institute of Oncology, Porto, Portugal
› Institutsangaben
› Weitere Informationen
   Lizenzen und Reprints

Abstract

Introduction At the time of diagnosis, treatment strategies for cancer are largely based upon clinical staging. However, discrepancy between clinical and pathological staging has been reported.

Objective To assess the rate of staging discrepancy in Laryngeal and Hypopharyngeal Squamous Cell Carcinoma (LHSCC), the potential influence of higher interval of time from diagnosis to primary surgical treatment, and whether this has any impact on survival outcomes.

Methods Retrospective study of patients with LHSCC proposed for primary surgical treatment.

Results The study population included 125 Caucasian patients with LHSCC. The level of agreement between clinical and pathological tumor staging was moderate (Cohen’s Kappa: 0.400; p < 0.001) and similar result was found for node staging (Cohen’ Kappa: 0.520; p < 0.001). The mean time between diagnosis and surgical treatment was 26.66 days and no statistically significant influence was found with staging discrepancy. The sample presented a 5-year Overall Survival (OS) of 58.2% and a Disease-specific survival (DSS) of 72.6%. No statistically significant impact of staging discrepancy on survival was found.

Conclusion For advanced LHSCC, based on the findings of physical examination, endoscopy and imaging, is possible to achieve a moderate accuracy between clinical and pathological staging which allows a reliable counselling and treatment planning. Interval of time under 3–4 weeks between diagnosis and surgical treatment does not influence the rate of discrepancy. However, almost 30% of staging discrepancy is expected due to false negatives of imaging and limitations of physical exams.

Keywords

survival - laryngeal cancer - hypopharyngeal cancer - cancer staging

Compliance with Ethical Standards

Ethical approval: All of the procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.


Informed consent: Informed consent was obtained from all individual participants included in the present study.


Financial Disclosure

The authors declare that they have no financial disclosure to declare.




Publikationsverlauf

Eingereicht: 25. März 2019

Angenommen: 19. Januar 2020

Artikel online veröffentlicht:
04. Mai 2020

© 2020. Fundação Otorrinolaringologia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

 

  • References

  • 1 Vermorken JB, Remenar E, van Herpen C. et al; EORTC 24971/TAX 323 Study Group. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007; 357 (17) 1695-1704
    CrossrefPubMedGoogle Scholar
  • 2 Eckel HE, Bradley PJ. Treatment Options for Hypopharyngeal Cancer. Adv Otorhinolaryngol 2019; 83: 47-53
    PubMedGoogle Scholar
  • 3 Habib A. Management of advanced hypopharyngeal carcinoma: systematic review of survival following surgical and non-surgical treatments. J Laryngol Otol 2018; 132 (05) 385-400
    CrossrefPubMedGoogle Scholar
  • 4 Lefebvre JL, Rolland F, Tesselaar M. et al; EORTC Head and Neck Cancer Cooperative Group, EORTC Radiation Oncology Group. Phase 3 randomized trial on larynx preservation comparing sequential vs alternating chemotherapy and radiotherapy. J Natl Cancer Inst 2009; 101 (03) 142-152
    CrossrefPubMedGoogle Scholar
  • 5 Posner MR, Norris CM, Wirth LJ. et al; TAX 324 Study Group. Sequential therapy for the locally advanced larynx and hypopharynx cancer subgroup in TAX 324: survival, surgery, and organ preservation. Ann Oncol 2009; 20 (05) 921-927
    CrossrefPubMedGoogle Scholar
  • 6 Forastiere AA, Zhang Q, Weber RS. et al. Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol 2013; 31 (07) 845-852
    CrossrefPubMedGoogle Scholar
  • 7 Scherl C, Mantsopoulos K, Semrau S. et al. Management of advanced hypopharyngeal and laryngeal cancer with and without cartilage invasion. Auris Nasus Larynx 2017; 44 (03) 333-339
    CrossrefPubMedGoogle Scholar
  • 8 Kim YJ, Lee R. Surgery vs. radiotherapy for locally advanced hypopharyngeal cancer in the contemporary era: A population-based study. Cancer Med 2018; 7 (12) 5889-5900
    CrossrefPubMedGoogle Scholar
  • 9 Celakovsky P, Kalfert D, Smatanova K, Kordac P, Laco J, Chrobok V. Discordance between clinical and pathological TNM classification: influence on results of treatment and prognosis in patients with laryngeal cancer. Neoplasma 2017; 64 (02) 305-310
    CrossrefPubMedGoogle Scholar
  • 10 Sobin LH, Gospodarowicz MK, Wittekind C. TMN Classification of Malignat Tumours, 7 th Edition. New York: Wiley-Blackwell; 2009: 336 ISBN 978–1-4443–3241–4.
    Google Scholar
  • 11 Biron VL, O'Connell DA, Seikaly H. The impact of clinical versus pathological staging in oral cavity carcinoma--a multi-institutional analysis of survival. J Otolaryngol Head Neck Surg 2013; 42 (01) 28
    CrossrefPubMedGoogle Scholar
  • 12 Daneshi N, Fararouei M, Mohammadianpanah M, Zare-Bandamiri M, Parvin S, Dianatinasab M. Effects of different treatment strategies and tumor stage on survival of patients with advanced laryngeal carcinoma: a 15-year cohort study. J Cancer Epidemiol 2018; 2018: 9678097
    CrossrefPubMedGoogle Scholar
  • 13 Greenberg JS, El Naggar AK, Mo V, Roberts D, Myers JN. Disparity in pathologic and clinical lymph node staging in oral tongue carcinoma. Implication for therapeutic decision making. Cancer 2003; 98 (03) 508-515
    CrossrefPubMedGoogle Scholar
  • 14 Pentenero M, Cistaro A, Brusa M. et al. Accuracy of 18F-FDG-PET/CT for staging of oral squamous cell carcinoma. Head Neck 2008; 30 (11) 1488-1496
    CrossrefPubMedGoogle Scholar
  • 15 Ashraf M, Biswas J, Jha J. et al. Clinical utility and prospective comparison of ultrasonography and computed tomography imaging in staging of neck metastases in head and neck squamous cell cancer in an Indian setup. Int J Clin Oncol 2011; 16 (06) 686-693
    CrossrefPubMedGoogle Scholar
  • 16 Barrera JE, Miller ME, Said S, Jafek BW, Campana JP, Shroyer KR. Detection of occult cervical micrometastases in patients with head and neck squamous cell cancer. Laryngoscope 2003; 113 (05) 892-896
    CrossrefPubMedGoogle Scholar
  • 17 Reis I, Aguiar A, Alzamora C. et al. Locally advanced hypopharyngeal squamous cell carcinoma: single-institution outcomes in a cohort of patients curatively treated either with or without larynx preservation. Radiol Bras 2016; 49 (01) 21-25
    CrossrefPubMedGoogle Scholar
  • 18 Kim SY, Rho YS, Choi EC. et al. Clinicopathological factors influencing the outcomes of surgical treatment in patients with T4a hypopharyngeal cancer. BMC Cancer 2017; 17 (01) 904
    CrossrefPubMedGoogle Scholar
  • 19 Koch WM, Ridge JA, Forastiere A, Manola J. Comparison of clinical and pathological staging in head and neck squamous cell carcinoma: results from Intergroup Study ECOG 4393/RTOG 9614. Arch Otolaryngol Head Neck Surg 2009; 135 (09) 851-858
    CrossrefPubMedGoogle Scholar